Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 06-1991 | |
| Cash Flows From Operating Activities | |
| Accounts receivable | -107,000 |
| Other Working Capital | -116,000 |
| Other Operating Activity | 838,000 |
| Operating Cash Flow | $615,000 |
| Cash Flows From Investing Activities | |
| PPE Investments | -578,000 |
| Other Investing Activity | -273,000 |
| Investing Cash Flow | $-851,000 |
| Cash Flows From Financing Activities | |
| Debt Issued | 2,312,000 |
| Debt Repayment | -1,859,000 |
| Common Stock Issued | 20,000 |
| Financing Cash Flow | $473,000 |
| Exchange Rate Effect | -9,000 |
| Beginning Cash Position | 189,000 |
| End Cash Position | 417,000 |
| Net Cash Flow | $237,000 |
| Free Cash Flow | |
| Operating Cash Flow | 615,000 |
| Capital Expenditure | -606,000 |
| Free Cash Flow | 9,000 |